Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Kristeleit · SciRah

Researcher profile · Semantic Scholar

R. Kristeleit

Share profile

R. Kristeleit — researcher profile on SciRah

h-index: 42
Works: 293
Citations: 8,130

Most-cited papers

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)
Bradley J. Monk, C. Parkinson, M. Lim, D. O'Malley +35 more
2022Journal of Clinical Oncology346 citations Open access
Semantic Scholar
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
A. Oaknin, L. Gilbert, A. Tinker, Jubilee Brown +18 more
2022Journal for ImmunoTherapy of Cancer307 citations Open access
Semantic Scholar
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
R. Kristeleit, A. Lisyanskaya, A. Fedenko, M. Dvorkin +21 more
2022The Lancet Oncology125 citations
Semantic Scholar
Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors
Thierry André, D. Berton, G. Curigliano, R. Sabatier +23 more
2023JAMA Network Open121 citations Open access
Semantic Scholar
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
A. Oaknin, B. Pothuri, L. Gilbert, R. Sabatier +17 more
2023Clinical Cancer Research83 citations Open access
Semantic Scholar
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes
H. Bax, Jitesh Chauhan, C. Stavraka, A. Santaolalla +32 more
2022British Journal of Cancer83 citations Open access
Semantic Scholar
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors
Elizabeth J. Davis, J. Martin-Liberal, R. Kristeleit, D. Cho +14 more
2022Journal for ImmunoTherapy of Cancer58 citations Open access
Semantic Scholar
Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer
R. Kristeleit, M. Devlin, A. Clamp, C. Gourley +12 more
2025JAMA Oncology42 citations Open access
Semantic Scholar
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
R. Kristeleit, R. Plummer, Robert Jones, L. Carter +10 more
2023British Journal of Cancer42 citations Open access
Semantic Scholar
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial
J. Spicer, B. Basu, A. Montes, U. Banerji +28 more
2023Nature Communications40 citations Open access
Semantic Scholar
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer
Robert Jones, R. Plummer, V. Moreno, L. Carter +12 more
2022Clinical Cancer Research38 citations Open access
Semantic Scholar
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
G. Curigliano, G. Shapiro, R. Kristeleit, A. A. Abdul Razak +15 more
2022British Journal of Cancer35 citations Open access
Semantic Scholar
The Tumor Microenvironment of Clear-Cell Ovarian Cancer
M. Devlin, Rowan E. Miller, Florian Laforêts, Panoraia Kotantaki +6 more
2022Cancer immunology research34 citations Open access
Semantic Scholar
Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
M. Mirza, S. Ghamande, L. Hanker, D. Black +16 more
2024Gynecologic Oncology32 citations
Semantic Scholar
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
J. Luke, M. Fakih, C. Schneider, E. Chiorean +11 more
2023British Journal of Cancer32 citations Open access
Semantic Scholar
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers
R. Kristeleit, A. Leary, A. Oaknin, A. Redondo +12 more
2024British Journal of Cancer27 citations Open access
Semantic Scholar
Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Susana Banerjee, G. Giannone, A. Clamp, D. Ennis +16 more
2023JAMA Oncology25 citations Open access
Semantic Scholar
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial.
A. M. Oza, A. Lisyanskaya, A. Fedenko, A. D. de Melo +20 more
2025The Lancet Oncology24 citations
Semantic Scholar
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
S. Nicum, N. McGregor, Rachel Austin, L. Collins +11 more
2024British Journal of Cancer24 citations Open access
Semantic Scholar
Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction
Gabriel Osborn, Jacobo López-Abente, Rebecca Adams, R. Laddach +24 more
2025Nature Communications21 citations Open access
Semantic Scholar
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study
R. Morgan, A. Clamp, Bethany M. Barnes, K. Timms +22 more
2023International Journal of Gynecological Cancer20 citations Open access
Semantic Scholar
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10
O. Colomban, E. Swisher, R. Kristeleit, I. McNeish +6 more
2023EBioMedicine20 citations Open access
Semantic Scholar
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
K. Nešić, J. Krais, C. Vandenberg, Yi-Fan Wang +30 more
2023medRxiv20 citations Open access
Semantic Scholar
Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
V. Moreno, D. Roda, J. Pikiel, J. Trigo +14 more
2022Clinical Lung Cancer19 citations Open access
Semantic Scholar
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study
T. Yap, Patricia M. Lorusso, Rowan E. Miller, R. Kristeleit +11 more
2025British Journal of Cancer15 citations Open access
Semantic Scholar
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
K. Nešić, J. Krais, Yi-Fan Wang, Cassandra J. Vandenberg +185 more
2024Molecular Cancer12 citations Open access
Semantic Scholar
Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab
R. Kristeleit, C. Mathews, A. Redondo, S. Boklage +3 more
2022International Journal of Gynecological Cancer12 citations Open access
Semantic Scholar
Life after SOLO-2: Is Olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi) resistant, recurrent ovarian cancer?
R. Kristeleit, K. Moore
2022Annals of Oncology12 citations Open access
Semantic Scholar
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10
R. Kristeleit, Y. Drew, A. Oza, S. Domchek +12 more
2022British Journal of Cancer11 citations Open access
Semantic Scholar
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)
Jung-Yun Lee, David Tan, I. Ray-Coquard, Jungbok Lee +11 more
2024Journal of Gynecologic Oncology10 citations Open access
Semantic Scholar
Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.
A. Oza, A. Lisyanskaya, A. Fedenko, M. Dvorkin +15 more
20218 citations
Semantic Scholar
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775
V. Makker, N. Colombo, Antonio Casado, A. Santin +26 more
2026Journal for ImmunoTherapy of Cancer7 citations Open access
Semantic Scholar
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
R. Kristeleit, A. Leary, J. Delord, V. Moreno +14 more
2023Investigational new drugs7 citations Open access
Semantic Scholar
Non‐Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First‐In‐Class IgE Antibody Recognising Folate Receptor Alpha
C. Stavraka, Jitesh Chauhan, Silvia Crescioli, S. McSweeney +25 more
2025Allergy. European Journal of Allergy and Clinical Immunology6 citations Open access
Semantic Scholar
LBA43 NAPISTAR 1-01: A phase I dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate (ADC) in patients with platinum-resistant ovarian (PROC) high grade serous carcinoma (HGSC)
A. González-Martín, J. Sehouli, E. Braicu, S. Sen +14 more
2025Annals of Oncology5 citations Open access
Semantic Scholar
Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.
D. O'Malley, B. Monk, M. Lim, José Fuentes Pradera +16 more
2024Journal of Clinical Oncology5 citations
Semantic Scholar
A three-arm randomized phase II study of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynecological clear cell carcinoma: DOVE (APGOT-OV7/ENGOT-ov80 study).
Jung-Yun Lee, David Shao Peng Tan, I. Ray-Coquard, Jungbok Lee +10 more
2024Journal of Clinical Oncology5 citations Open access
Semantic Scholar
76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial
A. Oaknin, L. Gilbert, A. Tinker, J. Brown +16 more
2021Annals of Oncology5 citations Open access
Semantic Scholar
1Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study
R. Kristeleit, A. Lisyanskaya, A. Fedenko, M. Dvorkin +21 more
2021Gynecologic Oncology5 citations
Semantic Scholar
272 Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study
A. Oaknin, L. Gilbert, A. Tinker, Jubilee Brown +15 more
2021Endometrial cancer5 citations Open access
Semantic Scholar
NAPISTAR 1-01: An international phase I/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).
T. van Gorp, A. González-Martín, Shiraj Sen, J. Sehouli +14 more
2025Journal of Clinical Oncology4 citations Open access
Semantic Scholar
774 A phase 1 study exploring the safety and tolerability of the small molecule PD-L1 inhibitor, INCB086550, in patients with select advanced tumors
C. le Tourneau, S. Piha-Paul, H. Prenen, B. Delafontaine +20 more
2022Regular and Young Investigator Award Abstracts4 citations Open access
Semantic Scholar
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre
B. Russell, C. Moss, E. Tsotra, C. Gousis +31 more
2022Cancers4 citations Open access
Semantic Scholar
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.
M. Powell, S. Ghamande, L. Hanker, Destin Black +27 more
2026International Journal of Gynecological Cancer3 citations Open access
Semantic Scholar
DDRiver EOC 302: A Randomised Phase 2 Study Of Tuvusertib With Niraparib Or Lartesertib In Patients With Epithelial Ovarian Cancer That Has Progressed On Prior PARP Inhibitor Therapy
R. Kristeleit, M. Mirza, Antonio Gonzalez Martin, Robert L. Coleman +5 more
2025International Journal of Gynecological Cancer3 citations Open access
Semantic Scholar
Interim safety and antitumor activity data from a phase 1 study of INCB123667, a selective CDK2 inhibitor, in patients with metastatic recurrent endometrial cancer.
D. Lorusso, Silvia Damian, I. Colombo, E. Wang +5 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
O026/#560 Efficacy analysis by disease risk subgroup for the phase 3 athena-mono study (GOG-3020/engot-OV45) evaluating rucaparib maintenance treatment in patients with newly diagnosed ovarian cancer
D. O'Malley, A. Christopoulou, M. Lim, J. Diaz +16 more
2022Focused Plenary Abstracts3 citations Open access
Semantic Scholar
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' reply.
R. Kristeleit, A. Oza
2022The Lancet Oncology3 citations
Semantic Scholar
2022-RA-1276-ESGO Pembrolizumab monotherapy for advanced clear cell gynaecological cancer: phase II PEACOCC trial
Rowan E. Miller, A. Clamp, C. Gourley, R. Roux +8 more
2022Ovarian cancer3 citations Open access
Semantic Scholar
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
Y. Drew, Lucy Gilbert, Alejandro Martinez Bueno, A. Oaknin +18 more
2026British Journal of Cancer2 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Oaknin×15
Invite
A. Oaknin — researcher profile on SciRah
S. Goble×8
Invite
S. Goble — researcher profile on SciRah
T. Safra×6
Invite
T. Safra — researcher profile on SciRah
I. McNeish×6
Invite
I. McNeish — researcher profile on SciRah

×6

Invite

K. Lin — researcher profile on SciRah

Invite

A. Oza — researcher profile on SciRah

Invite

D. Lorusso — researcher profile on SciRah

Invite

V. Boni — researcher profile on SciRah

A. Lisyanskaya×5

Invite

A. Lisyanskaya — researcher profile on SciRah

Invite

N. Colombo — researcher profile on SciRah

Invite

D. Cibula — researcher profile on SciRah

Rowan E. Miller×5

Invite

Rowan E. Miller — researcher profile on SciRah